IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked

IceCure Medical announced positive clinical data for its ProSense® cryoablation system at ECIO 2026, showing 89.4% recurrence-free rate for kidney tumors ≤3 cm and 100% excellent cosmetic outcomes in breast cancer patients. The company also reported 92.9% fibroadenoma volume reduction at 12 months. A dedicated breast cryoablation course was held for the first time at the conference, highlighting growing clinical validation and commercial interest in the technology.